PALVELLA THERAPEUTICS INC NasdaqCM:PVLA Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania

Location: 125 Strafford Avenue, Wayne, PA, 19087, United States | Website: https://palvellatx.com | Industry: Biotechnology | Sector: Healthcare